Download MendeleyA small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity.
Liang, S., Tran, E., Du, X., Dong, J., Sudholz, H., Chen, H., Qu, Z., Huntington, N.D., Babon, J.J., Kershaw, N.J., Zhang, Z.Y., Baell, J.B., Wiede, F., Tiganis, T.(2023) Nat Commun 14: 4524-4524
- PubMed: 37500611 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1038/s41467-023-40170-8
- Primary Citation Related Structures:
8SKL - PubMed Abstract:
The inhibition of protein tyrosine phosphatases 1B (PTP1B) and N2 (PTPN2) has emerged as an exciting approach for bolstering T cell anti-tumor immunity. ABBV-CLS-484 is a PTP1B/PTPN2 inhibitor in clinical trials for solid tumors. Here we have explored the therapeutic potential of a related small-molecule-inhibitor, Compound-182. We demonstrate that Compound-182 is a highly potent and selective active site competitive inhibitor of PTP1B and PTPN2 that enhances T cell recruitment and activation and represses the growth of tumors in mice, without promoting overt immune-related toxicities. The enhanced anti-tumor immunity in immunogenic tumors can be ascribed to the inhibition of PTP1B/PTPN2 in T cells, whereas in cold tumors, Compound-182 elicited direct effects on both tumor cells and T cells. Importantly, treatment with Compound-182 rendered otherwise resistant tumors sensitive to α-PD-1 therapy. Our findings establish the potential for small molecule inhibitors of PTP1B and PTPN2 to enhance anti-tumor immunity and combat cancer.
- Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, 3800, Australia.
Organizational Affiliation:
